athersys

Companies involved in researching medical techniques using stem cells saw shares tumble across the board Tuesday, a day after a federal court ruled to block government funding for stem cell research.

Long an old-line drug company, Pfizer is looking increasingly like a new biotech these days, especially after licensing a stem cell therapy. Athersys' MultiStem is a therapy that consists of a special class of stem cells obtained from the bone marrow of healthy, adult donors to treat inflammatory bowel disease.